Characteristics and Outcomes of Patients Admitted to Swedish Intensive Care Units for COVID-19
1 other identifier
observational
7,500
1 country
1
Brief Summary
This is a registry-based cohort study of all adult patients (≥18 years) admitted to Swedish Intensive Care Units with confirmed SARS-CoV-2 infection and COVID-19 disease during the first 2 months of the 2020 pandemic. The main goal is to describe demographic characteristics, coexisting conditions, treatments and outcomes among critically ill patients with COVID-19. A secondary goal is to identify independent risk factors associated with increased mortality for these patients. Data regarding baseline characteristics including comorbidities, intensive care treatments and outcomes will be extracted. ICU lengths of stay and 30-day mortalities will be calculated. The primary outcome is 30-day all-cause mortality. THIS PART OF THE STUDY HAS BEEN COMPLETED. UPDATE 26 Feb 2022: Characteristics and outcomes of 'first wave' patients admitted to Swedish ICUs was published in Eur J Anaesthesiol. 2021 Apr 1;38(4):335-343. doi: 10.1097/EJA.0000000000001459. A description of the surge response and aggregated data outcomes in Scandinavian countries was published in https://onlinelibrary.wiley.com/doi/10.1111/aas.13983. UPDATE 13 Nov 2024: ADDITIONAL SUMMARY - EXTENDED INCLUSION PERIOD AND ADDITION OF LONG-TERM OUTCOMES, AND CRITICALLY ILL PATIENTS WITH INFLUENZA AND VIRAL PNEUMONITIS Due to the continued influx of patients requiring intensive care due to COVID-19, we extended the inclusion period to 31 Dec 2022. Thus this new cohort will include all patients admitted to ICUs in Sweden from 6 March 2020 to 31 Dec 2022. We will investigate short (30day mortality) and long-term outcomes (365d mortality and cardiovascular complications) of patients admitted to Swedish ICUs with confirmed SARS-CoV-2 infection and COVID-19 disease. In international research, the long-term effects of ICU-requiring COVID-19 are now highly topical. Long-term follow-up exceeding one year has not yet been conducted on any Swedish material. To concretely understand the actual implications of long-term outcomes, it is becoming almost standard to compare this patient group to ICU-requiring influenza + viral pneumonitis patients to some extent. We have applied for and obtained ethical approval to include this group as a potential comparator to COVID-19 patients. However, such comparisons require careful consideration of potential confounders, such as patient characteristics and socioeconomic factors. It is therefore crucial to both establish the disease burden for the population and relate it to a comparable patient group. Ethical approval and national data linkage approvals have now been obtained to extract this data from Statistics Sweden and the Swedish National Board of Health and Welfare registries. Data linkage was completed in October 2024.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 6, 2020
CompletedFirst Submitted
Initial submission to the registry
July 6, 2020
CompletedFirst Posted
Study publicly available on registry
July 8, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedMarch 17, 2026
March 1, 2026
4.7 years
July 6, 2020
March 15, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
30-day mortality
all-cause
30 days
365-day mortality
all-cause
365 days (additional outcome added Oct 2021 after additional approval from ethical committee)
Secondary Outcomes (2)
ICU mortality
30 days
Morbidity
up to 365 days after study inclusion
Other Outcomes (1)
Mortality at longest follow-up
6 Mar 2020 to 31 Dec 2022
Interventions
All patients admitted to Swedish ICUs with COVID-19 between 6 Mar - 6 May 2020
Eligibility Criteria
Adult patients (≥18 years) admitted to Swedish Intensive Care Units with confirmed SARS-CoV-2 infection and COVID-19 disease during the first 2 months of the 2020 pandemic (6 March-6May2020).
You may qualify if:
- Adult patients (≥18 years)
- COVID-19 disease
You may not qualify if:
- No Swedish personal identity number
- 'Opt out' from Swedish Intensive Care Registry
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Linkoeping Universitylead
- Region Östergötlandcollaborator
Study Sites (1)
Department of Anaesthesia and Intensive Care, Linkoeping University Hospital, Region Östergötland
Linköping, Östergötland County, 50185, Sweden
Related Publications (1)
Chew MS, Blixt PJ, Ahman R, Engerstrom L, Andersson H, Berggren RK, Tegnell A, McIntyre S. National outcomes and characteristics of patients admitted to Swedish intensive care units for COVID-19: A registry-based cohort study. Eur J Anaesthesiol. 2021 Apr 1;38(4):335-343. doi: 10.1097/EJA.0000000000001459.
PMID: 33534266DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 6, 2020
First Posted
July 8, 2020
Study Start
March 6, 2020
Primary Completion
October 31, 2024
Study Completion (Estimated)
December 31, 2026
Last Updated
March 17, 2026
Record last verified: 2026-03